| __timestamp | Merck & Co., Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 4042025 |
| Thursday, January 1, 2015 | 10313000000 | 5279557 |
| Friday, January 1, 2016 | 9762000000 | 8073913 |
| Sunday, January 1, 2017 | 9830000000 | 44864073 |
| Monday, January 1, 2018 | 10102000000 | 53488904 |
| Tuesday, January 1, 2019 | 10615000000 | 65896361 |
| Wednesday, January 1, 2020 | 8955000000 | 69968267 |
| Friday, January 1, 2021 | 9634000000 | 92047281 |
| Saturday, January 1, 2022 | 10042000000 | 131819000 |
| Sunday, January 1, 2023 | 10504000000 | 87501000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Merck & Co., Inc. and Pharming Group N.V., from 2014 to 2023. Over this period, Merck's SG&A expenses have shown a slight decline, averaging around $10 billion annually, with a notable dip in 2020. In contrast, Pharming Group's expenses have surged by over 300%, peaking in 2022. This stark difference highlights the scale and strategic priorities of these companies. While Merck's expenses reflect its vast global operations, Pharming's growth trajectory suggests aggressive expansion and investment in market presence. Understanding these trends offers valuable insights into the operational strategies of pharmaceutical giants, emphasizing the balance between cost management and growth.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Pharming Group N.V. Trends and Insights
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Xenon Pharmaceuticals Inc. Trends and Insights